TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
The market for injectable limited PPI is anaemic: two varieties are growing at a rate of more than 40 per cent
 
Author:中国铭铉 企划部  Release Time:2017-5-22 10:22:21  Number Browse:696
 
The drug network May 22 is the most advanced class of drugs for treating peptic ulcers, and the market share is close to 90 percent. In the 2017 version of the health care drug catalog, the lizhu group's apprazole is the only one of the new proton pump inhibitors. The current domestically listed razole drugs include lansorazole, pantora, omeprazole, esomeprazole, rebelazole and prazole. 
 
Sample according to the domestic hospital statistics, in 2005, the six proton pump inhibitors samples of domestic hospital sales of 660 million yuan, 2009 annual sales of 2 billion yuan, sales have more than 5.3 billion yuan in 2016. After eight years of rapid growth, the overall market has slowed over the past two years. Among them, the orchid sola, panxi tora azole, omeprazole, esso beauty pull azole slightly weak growth of the four main products market a new generation of proton pump inhibitors rabeprazole azole and moxa oprah was active in the market. 
 
General situation of 
 
The products are all in the health care catalog 
 
At present domestic listed six proton pump inhibitor has fully into the medical insurance directory, respectively is orchid sola azole (injection + oral interpretation of dosage form), panxi tora azole (injection + oral interpretation of dosage form), omeprazole (injection + oral interpretation of dosage form), esso beauty pull azole (injection + oral interpretation of dosage form), rabeprazole azole (oral interpretation of dosage form), ai oprah azole (oral interpretation of dosage form). 
 
Version of health care in 2017 the list of drugs, proton pump inhibitor injection all become the object of payment scope, the limited scope for "limit is marked by the instructions of disease diagnosis and fast orders or dysphagia patients". Some of the adjustments from the PPI injection dosage form of the health care drug catalog can be used to peer into the country's guidelines on compliance. Since the PPI has a larger market share in injection dosage, the scope of this payment will be significantly more affected by the pattern of drug use. The innovation medicine method, in the new directory oprah azole for oral interpretation of the dosage form, also among the payment scope, the limited scope for "patients with duodenal ulcer in the diagnosis of second-line drugs". 
 
The injection was 68.5% 
 
In 2016, orchid sola, panxi tora etc, omeprazole three products are close to or more than $1 billion in sales blockbuster products, esso beauty pull azole, rabeprazole thiazole was also the big product sales of nearly 800 million yuan, especially the thunder azole Bella is growing rapidly in 2016. In addition, the innovative drug, prazole, has already sold more than 100 million yuan in 2016. 
 
In 2016, the sales of proton pump inhibitor injections totaled 36.6 billion yuan, accounting for 68.5 percent of the total market, according to the domestic sample hospital. Oral dosage form sales were 1.69 billion yuan, or 31.5 percent. Among them, lansorazole sales were 1.42 billion yuan, and the injections accounted for 88.2% and oral dosage forms 11.8%. The sales of pantolazole were 1.26 billion yuan, 76.5 percent of the injections and 23.5 percent of oral dosage forms. Omeprazole sales were 994 million yuan, the injections accounted for 82.4 percent, and oral dosage forms 17.6 percent. The sales of esomeprazole were 795 million yuan, with an injection of 55.2% and oral dosage of 44.8%. Rabeprazole azole sales of 758 million yuan, injection (25.6%), oral dosage forms (74.4%), ray azole Bella is the only one oral dosage forms sales of more than injection products; Prazole's oral dosage form is 120 million yuan. 
 
The TOP five companies make up half the mountain 
 
In 2016, domestic production of the sample hospitals involved in proton pump inhibitors is more than 140 enterprises, the top five companies: jiangsu orsay kang products sales of 997 million yuan, accounting for 18.6%; Astrazeneca's sales were 8.1 billion yuan, or 15.0 percent. Shandong roxin pharmaceutical co., which has sales of 4.4 billion yuan, accounted for 8.2%. Nycomed's sales were 336 million yuan, or 6.3 percent. The sales of changzhou's pharmaceutical products were 264 million yuan, or 4.9 percent. The top five companies totaled 28.4 billion yuan, or 53.1 percent of the overall market. 
 
The top of the list is jiangsu, which has five products listed on the list. Among them, omeprazole had a 50.5% share, and lansorazole accounted for 46.0%, and other products, such as rebelazole, pazolazole and esomeprazole, accounted for 3.6% of the total. 
 
varieties 
 
Leibelazole is growing strongly 
 
Rabeprazole azole developed by eisai Japan company, for benzene and imidazole derivatives, belong to the new proton pump inhibitors, for the first time in 1997 in Japan, commodity called "Pariet". The Japanese company, which was listed in the UK and Germany in 1998 and listed in the us in 1999, became the world's best-selling drug. 
 
According to the domestic sample hospital, the dosage forms sold in the market are oral and powders. In 2016, the sales of tablets were 365 million yuan, or 48.1%. The sales of capsules were 199 million yuan, or 26.3 percent. Sales of powdered needles were 194 million yuan, or 25.6 percent. From the dosage form, the product is dominated by oral dosage form. In the first five years of the product, the market has been unheated, starting at about five years, especially in 2016, with a 43.6% increase over the same period. 
 
At present, there are 13 companies participating in the market. In 2016, sales of the top five companies is eisai pharmaceutical (suzhou), jiangsu nanjing long Australian pharmaceutical, Jiang Suji dickon pharmaceutical pharmaceutical, sichuan chengdu in sichuan province, jiangsu, pharmaceutical industry, sales of 146 million yuan, 129 million yuan respectively, 116 million yuan, 73.04 million yuan and 70.03 million yuan. Among them, eisai (suzhou) pharmaceutical pollitt accounted for 19.3%, jiangsu nanjing long Australian pharmaceutical products accounted for 17.1%, Jiang Suji sichuan pharmaceutical products accounted for 15.3%, top five enterprises occupy 70.6% market share. 
 
Notable is, ray Bella azole sodium for injection after become injection with proton pump inhibitors market to be bestowed favor on newly, pull the rabeprazole rapid growth of the market. At present domestic three companies related products on the market of nanjing long Australian pharmaceutical products in May 2014 the first listed, jiangsu orsay kang pharmaceutical products listed in December 2014, shandong rossing pharmaceutical group products on the market in June 2015. In the past three years, SJM, which is the first imitative drug, has performed the best in the market, with a 2.5 times increase in 2016. 
 
It's called the prazole frequency 
 
Ai oprah azole is a potent ion pump inhibitor, in December 2007, approved by method group, commodity called "one lian", dosage form for enteric-coated metformin hydrochloride, specifications for 5 mg. The product to be group of independent innovation of new drugs, has been applied for, the United States and the European Union, Australia, Japan, and a number of countries such as invention patent, become the company's new profit growth point method. In January 2016, the product was awarded the second prize of the national science and technology advance in 2015, and the market has been singing all the way in the last five years. 
 
Hospital according to the sample data statistics, in 2008 Mr Azole sales of 870000 yuan, 2015 sales of 2015 yuan, up 42.9% from a year earlier, rapid growth, 2016 annual sales of 128 million yuan, up 42.2% from a year earlier. In the past two years, the market has exploded, and the momentum has not been underestimated. 
 
The lizhu group is developing new indications and new dosage forms on the basis of eprazole. Is be moxa tripura azole sodium for injection group independent research and development of the second generation of proton pump inhibitors, the product in October 2016 as a major projects and has significant clinical value innovation medicine access to priority review. At present only lizhu group, jiangsu otheca is the only one to declare. From the reporting schedule, lizhu group leads. 
 
In recent years, some domestic pharmaceutical enterprise independent research and development of innovative medicine, as it comes to the price of imported drugs will soon shrink, both from the drug safety and the price to bring many benefits to patients. Recently, exclusive product group method oprah azole enteric-coated metformin hydrochloride in the new national health care medicine catalogue, will help to the promotion of thiazole enteric-coated metformin hydrochloride, sales channels will widen further, for the future ai oprah azole laid the foundation for better injection after promotion. 
 
epilogue 
 
For most diseases especially in patients with chronic diseases patients, oral medicine is undoubtedly the most appropriate dosage regimen, but clinically PPI is very widely used for injection. The rapid growth of the PPI is expected to be unsustainable, with the gradual arrival of rational drug policies, such as domestic drug use and limited infusion. 
 
Although due to factors such as health care limit the market growth is slowing, but a new generation of proton pump inhibitors rapid market growth, and PPI new competitors to join, to keep the overall market is still growing trend. 
 
Previous article:The state council has made changes 《Regulations on the supervision and administration of medical devices 》The decision of the
Next article:Sanjia hospital selects medical consumables distributor: "one ticket system" first!
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粤公网安备 44011202000029号